GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)

Market Cap	439.94B -1.9%
Revenue (ttm)	39.55B +5.8%
Net Income	10.68B +12.4%
EPS	63.05 +12.4%
Shares Out	n/a
PE Ratio	41.19
Forward PE	36.51
Dividend	57.00 (2.18%)
Ex-Dividend Date	May 29, 2026

Volume	34,012
Open	2,617.00
Previous Close	2,601.00
Day's Range	2,577.00 - 2,617.00
52-Week Range	2,088.10 - 2,883.40
Beta	0.06
Analysts	Buy
Price Target	3,081.00 (+18.5%)
Earnings Date	Aug 3, 2026

About NSE:GLAXO

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers adult and pediatric vaccines, such as Shingrix, Havrix, Fluarix Tetra, Varilrix, Infanrix Hexa, Boostrix, Synflorix, Menveo, and Priorix. It also provides respiratory specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; Trelegy Ellipta for the treatment of chronic obstructive pulmonary disease; and Seretide. ...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1924
• Employees: 3,103
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: GLAXO

Financial Performance

In fiscal year 2026, NSE:GLAXO's revenue was 38.22 billion, an increase of 1.93% compared to the previous year's 37.49 billion. Earnings were 10.36 billion, an increase of 11.69%.

Analyst Summary

According to 4 analysts, the average rating for GLAXO stock is "Buy." The 12-month stock price target is ₹3,081, which is an increase of 18.50% from the latest price.

Price Target

₹3,081

(18.50% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 11, 2026

Data Sources Report a data error